Nordic Nanovector to Present at DNB’s 11[th] Annual Nordic Healthcare Conference
Oslo, Norway, 7 December 2020
Nordic Nanovector ASA (OSE: NANOV) announces that its Interim CEO, Dr Lars Nieba will present a corporate overview via live webcast at DNB’s 11th Annual Nordic Healthcare Conference, taking place on 15 December 2020.
Presentations details are as follows:
DNB’s 11th Annual Nordic Healthcare Conference
Date: 15 December 2020
Time: 09:50 to 10:10 (CET)
The presentation will be available at the same time at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Presentations.
For further information, please contact:
IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.
Further information can be found at www.nordicnanovector.com.
This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.
Tags: